177 related articles for article (PubMed ID: 37578980)
21. Reinterpretation of BRCA1 and BRCA2 variants of uncertain significance in patients with hereditary breast/ovarian cancer using the ACMG/AMP 2015 guidelines.
So MK; Jeong TD; Lim W; Moon BI; Paik NS; Kim SC; Huh J
Breast Cancer; 2019 Jul; 26(4):510-519. PubMed ID: 30725392
[TBL] [Abstract][Full Text] [Related]
22. BRCA1 and BRCA2 unclassified variants and missense polymorphisms in Algerian breast/ovarian cancer families.
Cherbal F; Salhi N; Bakour R; Adane S; Boualga K; Maillet P
Dis Markers; 2012; 32(6):343-53. PubMed ID: 22684231
[TBL] [Abstract][Full Text] [Related]
23. DNA repair-related functional assays for the classification of BRCA1 and BRCA2 variants: a critical review and needs assessment.
Toland AE; Andreassen PR
J Med Genet; 2017 Nov; 54(11):721-731. PubMed ID: 28866612
[TBL] [Abstract][Full Text] [Related]
24. Combining Homologous Recombination and Phosphopeptide-binding Data to Predict the Impact of
Petitalot A; Dardillac E; Jacquet E; Nhiri N; Guirouilh-Barbat J; Julien P; Bouazzaoui I; Bonte D; Feunteun J; Schnell JA; Lafitte P; Aude JC; Noguès C; Rouleau E; Lidereau R; Lopez BS; Zinn-Justin S; Caputo SM;
Mol Cancer Res; 2019 Jan; 17(1):54-69. PubMed ID: 30257991
[No Abstract] [Full Text] [Related]
25. Integration of functional assay data results provides strong evidence for classification of hundreds of BRCA1 variants of uncertain significance.
Lyra PCM; Nepomuceno TC; de Souza MLM; Machado GF; Veloso MF; Henriques TB; Dos Santos DZ; Ribeiro IG; Ribeiro RS; Rangel LBA; Richardson M; Iversen ES; Goldgar D; Couch FJ; Carvalho MA; Monteiro ANA
Genet Med; 2021 Feb; 23(2):306-315. PubMed ID: 33087888
[TBL] [Abstract][Full Text] [Related]
26. Validation and Data-Integration of Yeast-Based Assays for Functional Classification of BRCA1 Missense Variants.
Bellè F; Mercatanti A; Lodovichi S; Congregati C; Guglielmi C; Tancredi M; Caligo MA; Cervelli T; Galli A
Int J Mol Sci; 2022 Apr; 23(7):. PubMed ID: 35409408
[TBL] [Abstract][Full Text] [Related]
27. Impact of proactive high-throughput functional assay data on BRCA1 variant interpretation in 3684 patients with breast or ovarian cancer.
Kim HK; Lee EJ; Lee YJ; Kim J; Kim Y; Kim K; Lee SW; Chang S; Lee YJ; Lee JW; Lee W; Chun S; Son BH; Jung KH; Kim YM; Min WK; Ahn SH
J Hum Genet; 2020 Mar; 65(3):209-220. PubMed ID: 31907386
[TBL] [Abstract][Full Text] [Related]
28. Missense variants of uncertain significance (VUS) altering the phosphorylation patterns of BRCA1 and BRCA2.
Tram E; Savas S; Ozcelik H
PLoS One; 2013; 8(5):e62468. PubMed ID: 23704879
[TBL] [Abstract][Full Text] [Related]
29. Classification of BRCA1 missense variants of unknown clinical significance.
Phelan CM; Dapic V; Tice B; Favis R; Kwan E; Barany F; Manoukian S; Radice P; van der Luijt RB; van Nesselrooij BP; Chenevix-Trench G; kConFab ; Caldes T; de la Hoya M; Lindquist S; Tavtigian SV; Goldgar D; Borg A; Narod SA; Monteiro AN
J Med Genet; 2005 Feb; 42(2):138-46. PubMed ID: 15689452
[TBL] [Abstract][Full Text] [Related]
30. BRCA1/2 missense mutations and the value of in-silico analyses.
Sadowski CE; Kohlstedt D; Meisel C; Keller K; Becker K; Mackenroth L; Rump A; Schröck E; Wimberger P; Kast K
Eur J Med Genet; 2017 Nov; 60(11):572-577. PubMed ID: 28807866
[TBL] [Abstract][Full Text] [Related]
31. Characterization of BRCA1 and BRCA2 variants found in a Norwegian breast or ovarian cancer cohort.
Jarhelle E; Riise Stensland HM; Mæhle L; Van Ghelue M
Fam Cancer; 2017 Jan; 16(1):1-16. PubMed ID: 27495310
[TBL] [Abstract][Full Text] [Related]
32. Comprehensive evaluation and efficient classification of BRCA1 RING domain missense substitutions.
Clark KA; Paquette A; Tao K; Bell R; Boyle JL; Rosenthal J; Snow AK; Stark AW; Thompson BA; Unger J; Gertz J; Varley KE; Boucher KM; Goldgar DE; Foulkes WD; Thomas A; Tavtigian SV
Am J Hum Genet; 2022 Jun; 109(6):1153-1174. PubMed ID: 35659930
[TBL] [Abstract][Full Text] [Related]
33. Assessing BRCA1 activity in DNA damage repair using human induced pluripotent stem cells as an approach to assist classification of BRCA1 variants of uncertain significance.
Ozgencil M; Barwell J; Tischkowitz M; Izatt L; Kesterton I; Simpson M; Sharpe P; de Sepulveda P; Voisset E; Solomon E
PLoS One; 2021; 16(12):e0260852. PubMed ID: 34855882
[TBL] [Abstract][Full Text] [Related]
34. Functional analysis and clinical classification of 462 germline BRCA2 missense variants affecting the DNA binding domain.
Hu C; Huang H; Na J; Lumby C; Abozaid M; Holdren MA; Rao TJ; Karam R; Pesaran T; Weyandt JD; Csuy CM; Seelaus CA; Young CC; Fulk K; Heidari Z; Morais Lyra PC; Couch RE; Persons B; Polley EC; Gnanaolivu RD; Boddicker NJ; Monteiro ANA; Yadav S; Domchek SM; Richardson ME; Couch FJ
Am J Hum Genet; 2024 Mar; 111(3):584-593. PubMed ID: 38417439
[TBL] [Abstract][Full Text] [Related]
35. Functional Analyses of Rare Germline Missense
Hovland HN; Mchaina EK; Høberg-Vetti H; Ariansen SL; Sjursen W; Van Ghelue M; Haukanes BI; Knappskog PM; Aukrust I; Ognedal E
Genes (Basel); 2023 Jan; 14(2):. PubMed ID: 36833189
[TBL] [Abstract][Full Text] [Related]
36. A new bioinformatics tool to help assess the significance of BRCA1 variants.
Cusin I; Teixeira D; Zahn-Zabal M; Rech de Laval V; Gleizes A; Viassolo V; Chappuis PO; Hutter P; Bairoch A; Gaudet P
Hum Genomics; 2018 Jul; 12(1):36. PubMed ID: 29996917
[TBL] [Abstract][Full Text] [Related]
37. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals.
Kuusisto KM; Bebel A; Vihinen M; Schleutker J; Sallinen SL
Breast Cancer Res; 2011 Feb; 13(1):R20. PubMed ID: 21356067
[TBL] [Abstract][Full Text] [Related]
38. Combined annotation-dependent depletion score for BRCA1/2 variants in patients with breast and/or ovarian cancer.
Nakagomi H; Mochizuki H; Inoue M; Hirotsu Y; Amemiya K; Sakamoto I; Nakagomi S; Kubota T; Omata M
Cancer Sci; 2018 Feb; 109(2):453-461. PubMed ID: 29215753
[TBL] [Abstract][Full Text] [Related]
39. Compromised BRCA1-PALB2 interaction is associated with breast cancer risk.
Foo TK; Tischkowitz M; Simhadri S; Boshari T; Zayed N; Burke KA; Berman SH; Blecua P; Riaz N; Huo Y; Ding YC; Neuhausen SL; Weigelt B; Reis-Filho JS; Foulkes WD; Xia B
Oncogene; 2017 Jul; 36(29):4161-4170. PubMed ID: 28319063
[TBL] [Abstract][Full Text] [Related]
40. Variants of uncertain significance in BRCA1 and BRCA2 assessment of in silico analysis and a proposal for communication in genetic counselling.
Moghadasi S; Hofland N; Wouts JN; Hogervorst FB; Wijnen JT; Vreeswijk MP; van Asperen CJ
J Med Genet; 2013 Feb; 50(2):74-9. PubMed ID: 23231788
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
